LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

Conditions: TNBC - Triple-Negative Breast Cancer Interventions: Drug: LM-108; Drug: Toripalimab; Drug: Eribulin; Drug: Nab paclitaxel Sponsors: Fudan University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials